Peter Barry

838 total citations
39 papers, 414 citations indexed

About

Peter Barry is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Genetics. According to data from OpenAlex, Peter Barry has authored 39 papers receiving a total of 414 indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Pulmonary and Respiratory Medicine, 8 papers in Surgery and 6 papers in Genetics. Recurrent topics in Peter Barry's work include Cystic Fibrosis Research Advances (27 papers), Neonatal Respiratory Health Research (9 papers) and Tracheal and airway disorders (7 papers). Peter Barry is often cited by papers focused on Cystic Fibrosis Research Advances (27 papers), Neonatal Respiratory Health Research (9 papers) and Tracheal and airway disorders (7 papers). Peter Barry collaborates with scholars based in United Kingdom, United States and Ireland. Peter Barry's co-authors include Andrew Jones, Alex Horsley, Barry J. Plant, Nicholas J. Simmonds, Jennifer L. Taylor‐Cousar, Varinder Athwal, R.J. Bright-Thomas, Daniel Tewkesbury, Patrick A. Flume and Nadia Shafi and has published in prestigious journals such as CHEST Journal, BMJ and Journal of Hepatology.

In The Last Decade

Peter Barry

31 papers receiving 406 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Barry United Kingdom	13	310	44	43	42	37	39	414
Melissa Gans United States	6	65 0.2×	30 0.7×	44 1.0×	16 0.4×	30 0.8×	21	305
KW Tsang Hong Kong	9	320 1.0×	38 0.9×	50 1.2×	93 2.2×	17 0.5×	11	444
Linden A. Green United States	13	111 0.4×	99 2.3×	114 2.7×	74 1.8×	51 1.4×	20	388
János Szederjesi Romania	10	54 0.2×	59 1.3×	50 1.2×	63 1.5×	50 1.4×	36	259
Ulrike Zwergel Germany	10	407 1.3×	130 3.0×	123 2.9×	21 0.5×	7 0.2×	34	690
Shigeyuki Aoki Japan	11	207 0.7×	98 2.2×	86 2.0×	46 1.1×	17 0.5×	51	397
C. Richards United States	6	62 0.2×	38 0.9×	66 1.5×	49 1.2×	20 0.5×	19	278
Seiji Noma Japan	11	93 0.3×	138 3.1×	84 2.0×	26 0.6×	25 0.7×	19	365
Irene Heimbeck Germany	10	100 0.3×	19 0.4×	61 1.4×	52 1.2×	11 0.3×	11	372
Nikolaos Chaliasos Greece	11	27 0.1×	37 0.8×	74 1.7×	45 1.1×	34 0.9×	37	355

Countries citing papers authored by Peter Barry

Since Specialization

Citations

This map shows the geographic impact of Peter Barry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Barry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Barry more than expected).

Fields of papers citing papers by Peter Barry

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Barry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Barry. The network helps show where Peter Barry may publish in the future.

Co-authorship network of co-authors of Peter Barry

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Barry. A scholar is included among the top collaborators of Peter Barry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Barry. Peter Barry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cytlak, Urszula, Peter Barry, Edward Emmott, et al.. (2025). Effect of elexacaftor/tezacaftor/ivacaftor on systemic inflammation in cystic fibrosis. Thorax. 80(9). 604–615.

Pickles, Joanna, et al.. (2024). Role for DPP4 inhibitor therapy in cystic fibrosis related diabetes: A single centre experience. Journal of Cystic Fibrosis. 23(5). 853–856. 4 indexed citations

Barry, Peter, et al.. (2023). Identifying the need for a UK colorectal cancer screening programme for patients with cystic fibrosis (CF): 10-year retrospective review of colonoscopy and colorectal cancer outcomes at a single CF centre. BMJ Open Gastroenterology. 10(1). e001178–e001178. 1 indexed citations

Scott, Jennifer A., Andrew Jones, Timothy T. Gordon‐Walker, et al.. (2023). Improving detection of cystic fibrosis related liver disease using liver fibrosis assessment tools. Heliyon. 9(11). e21861–e21861. 5 indexed citations

Tewkesbury, Daniel, Varinder Athwal, R.J. Bright-Thomas, Andrew Jones, & Peter Barry. (2023). Longitudinal effects of elexacaftor/tezacaftor/ivacaftor on liver tests at a large single adult cystic fibrosis centre. Journal of Cystic Fibrosis. 22(2). 256–262. 33 indexed citations

Barry, Peter & Nicholas J. Simmonds. (2023). Diagnosing Cystic Fibrosis in Adults. Seminars in Respiratory and Critical Care Medicine. 44(2). 242–251. 6 indexed citations

Vasant, Dipesh H., et al.. (2023). WS08.04 Faecal Immunochemical Testing – ‘FIT’ for purpose for bowel screening in older cystic fibrosis patients?. Journal of Cystic Fibrosis. 22. S17–S17.

Tewkesbury, Daniel, Jennifer A. Scott, Peter Barry, et al.. (2023). Effects of elexacaftor/tezacaftor/ivacaftor on liver fibrosis markers in adults with cystic fibrosis. Journal of Cystic Fibrosis. 23(2). 349–353. 8 indexed citations

Barry, Peter, Edward Emmott, Andrew Jones, et al.. (2023). Influence of highly effective modulator therapy on the sputum proteome in cystic fibrosis. Journal of Cystic Fibrosis. 23(2). 269–277. 14 indexed citations

10.

Carey, Charles, et al.. (2022). A case of malignant stroke requiring hemicraniectomy following bronchial artery embolisation. Respiratory Medicine Case Reports. 39. 101730–101730.

11.

Walmsley, John, Javaid Iqbal, R.J. Bright-Thomas, et al.. (2021). HFR-7 Preventable early colorectal cancer in cystic fibrosis: is there ‘scope’ for a UK screening programme?. Research Explorer (The University of Manchester). A38.1–A38.

12.

Jones, Andrew, et al.. (2021). Longitudinal effects of ivacaftor and medicine possession ratio in people with theGly551Aspmutation: a 5-year study. Thorax. 76(9). 874–879. 23 indexed citations

13.

Scott, Jennifer A., Peter Barry, Andrew Jones, & Varinder Athwal. (2020). Management of superior mesenteric venous thrombus in cystic fibrosis related liver disease. Paediatric Respiratory Reviews. 35. 106–108.

14.

Jones, Andrew, Emma Davies, William Welfare, et al.. (2020). Influenza B outbreak at an adult cystic fibrosis centre - Clinical impact and factors influencing spread. Journal of Cystic Fibrosis. 19(5). 808–814. 5 indexed citations

15.

Barry, Peter, et al.. (2018). Ivacaftor for cystic fibrosis. BMJ. 361. k1783–k1783. 5 indexed citations

16.

Jones, Andrew, et al.. (2018). CFTR modulator therapy in patients with cystic fibrosis and an organ transplant. Paediatric Respiratory Reviews. 27. 6–8. 15 indexed citations

17.

Schwarz, C., Dominik Hartl, Olaf Eickmeier, et al.. (2017). Progress in Definition, Prevention and Treatment of Fungal Infections in Cystic Fibrosis. Mycopathologia. 183(1). 21–32. 46 indexed citations

18.

Lord, Robert, Andrew Jones, A.K. Webb, & Peter Barry. (2016). Pneumothorax in cystic fibrosis: beyond the guidelines. Paediatric Respiratory Reviews. 20. 30–33. 5 indexed citations

19.

Barry, Peter & Andrew Jones. (2015). New and Emerging Treatments for Cystic Fibrosis. Drugs. 75(11). 1165–1175. 12 indexed citations

20.

Barry, Peter, Barry J. Plant, Arjun Nair, et al.. (2014). Effects of Ivacaftor in Patients With Cystic Fibrosis Who Carry the G551D Mutation and Have Severe Lung Disease. CHEST Journal. 146(1). 152–158. 77 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact